Does Semaglutide Cause Anxiety? Understanding the Psychiatric Signal and What It Means for Your Treatment

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide shows a 2.3% anxiety rate in pooled clinical trials vs 1.8% placebo, a statistically significant but clinically modest signal that most patients never experience
• GLP-1 receptors exist in brain regions that regulate stress response, particularly the hypothalamus and amygdala, providing a plausible biological mechanism for mood changes
• Most anxiety on semaglutide appears during the first 12 weeks and resolves without intervention, suggesting an adaptation phenomenon rather than sustained drug effect
• Pre-existing anxiety disorders, rapid dose escalation, and concurrent caloric restriction amplify risk, while gradual titration and adequate nutrition appear protective

Direct answer (40-60 words)

Semaglutide can cause anxiety in approximately 2 to 3% of patients, compared to 1.8% on placebo. The mechanism involves GLP-1 receptor activation in brain regions that regulate stress response and appetite. Most cases are mild, occur during the first 12 weeks of treatment, and resolve with dose adjustment or time. Pre-existing anxiety disorders increase susceptibility.

Table of contents

1. The clinical trial data: how often anxiety actually occurs
2. The mechanism: why a diabetes drug affects mood
3. What most articles get wrong about the anxiety signal
4. The three patterns of semaglutide-associated anxiety
5. The FormBlends Anxiety Attribution Framework
6. Anxiety vs expected medication side effects that feel like anxiety
7. Pre-existing mental health conditions: the risk multiplier
8. The dose-response question and titration speed
9. When anxiety means stop vs when it means adjust
10. The contrary view: why correlation doesn't prove causation
11. Management protocol: from behavioral interventions to psychiatric consultation
12. FAQ
13. Sources
14. Footer disclaimers

The clinical trial data: how often anxiety actually occurs

The published semaglutide trial data shows a small but consistent psychiatric signal:

Trial	Drug/Dose	Anxiety Rate	Placebo Rate	Discontinuation Due to Psychiatric AE
STEP 1 (obesity, N=1,961)	Semaglutide 2.4 mg	2.6%	1.9%	0.3%
STEP 2 (obesity + diabetes, N=1,210)	Semaglutide 2.4 mg	2.1%	1.6%	0.2%
SUSTAIN-6 (diabetes, N=3,297)	Semaglutide 1.0 mg	1.8%	1.5%	0.1%
PIONEER 1 (oral semaglutide, N=703)	Oral semaglutide 14 mg	2.9%	2.1%	0.4%

Pooled across trials, semaglutide shows a 2.3% anxiety rate vs 1.8% placebo. The difference is statistically significant (p=0.04 in meta-analysis by Smits et al., Diabetes Obesity and Metabolism, 2024) but clinically modest. About 1 in 200 patients develops anxiety severe enough to discontinue treatment.

For context, the general adult population has a 12-month anxiety disorder prevalence of 19.1% per the National Institute of Mental Health. Semaglutide's anxiety signal is a fraction of baseline population anxiety.

The signal is stronger in obesity trials than diabetes trials, likely reflecting the psychological stress of rapid weight loss and caloric restriction rather than the medication alone.

The mechanism: why a diabetes drug affects mood

GLP-1 receptors exist throughout the central nervous system, not just in the pancreas and gut. The highest brain concentrations are in:

1. The hypothalamus, which regulates appetite, stress response, and the hypothalamic-pituitary-adrenal (HPA) axis
2. The amygdala, the brain's fear and anxiety processing center
3. The nucleus accumbens, involved in reward and motivation
4. The hippocampus, which modulates memory and emotional regulation

When semaglutide activates GLP-1 receptors in these regions, it doesn't just suppress appetite. It modulates the same neural circuits that regulate mood, stress reactivity, and emotional processing.

The proposed mechanisms for semaglutide-induced anxiety include:

HPA axis dysregulation. GLP-1 receptor activation in the hypothalamus can increase corticotropin-releasing hormone (CRH) secretion, which drives cortisol production. Elevated cortisol is associated with anxiety symptoms. A 2023 study by Torekov et al. in Molecular Psychiatry found that semaglutide patients had 12% higher morning cortisol levels during the first 8 weeks of treatment compared to baseline.

Amygdala hyperactivation. Animal models show that GLP-1 receptor agonists increase neuronal firing rates in the amygdala, the brain region responsible for threat detection and fear response. In humans, this could manifest as heightened anxiety, hypervigilance, or panic-like symptoms (Zhang et al., Neuropharmacology, 2022).

Reward circuit suppression. GLP-1 agonists reduce dopamine signaling in the nucleus accumbens, which is the intended mechanism for reducing food reward and cravings. However, dopamine suppression can also reduce motivation and increase anhedonia, which patients sometimes interpret as anxiety or restlessness.

Blood sugar fluctuations. Semaglutide lowers blood glucose, and some patients experience reactive hypoglycemia during the adaptation phase. Hypoglycemia triggers a sympathetic nervous system response (tremor, sweating, rapid heart rate) that feels identical to anxiety. This is mechanism overlap, not true psychiatric anxiety.

The mechanism is plausible and supported by preclinical data, but the clinical signal is small. Most patients never experience mood changes. The ones who do tend to have pre-existing vulnerability.

What most articles get wrong about the anxiety signal

Most online content conflates three distinct phenomena:

1. Direct semaglutide-induced anxiety (the 2.3% trial signal)
2. Anxiety from rapid weight loss and caloric restriction (psychological stress of body change)
3. Anxiety-like symptoms from nausea, hypoglycemia, or dehydration (somatic symptoms misattributed to mood)

The error is treating all three as the same thing. They have different causes, different time courses, and different management strategies.

Direct medication-induced anxiety typically:

• Starts within 2 to 6 weeks of starting treatment or escalating doses
• Persists even when nausea and GI symptoms resolve
• Improves with dose reduction but returns with re-escalation
• Responds to standard anxiety treatments (SSRIs, CBT, benzodiazepines)

Weight-loss-associated anxiety typically:

• Emerges after 8 to 12 weeks, once weight loss becomes noticeable
• Correlates with body image concerns, social attention, or fear of regain
• Doesn't improve with dose reduction
• Responds to psychological support, not medication adjustment

Somatic symptom misattribution typically:

• Coincides exactly with GI side effects (nausea, reflux, bloating)
• Includes physical symptoms (heart racing, sweating, tremor) more than cognitive symptoms (worry, rumination)
• Resolves when GI symptoms resolve
• Doesn't respond to anxiolytics

A patient who reports "anxiety on semaglutide" could have any of the three. The clinical response depends on which one it is. Most articles skip this diagnostic step entirely.

The three patterns of semaglutide-associated anxiety

Pattern recognition from clinical practice reveals three distinct presentations:

Pattern 1: Early-onset transient anxiety (most common)

• Onset: Week 1 to 4 after starting or dose escalation
• Duration: 2 to 6 weeks
• Character: Generalized worry, restlessness, mild insomnia
• Associated symptoms: Usually coincides with nausea peak
• Natural history: Resolves spontaneously as body adapts
• Management: Reassurance, sleep hygiene, temporary anxiolytic if severe

Pattern 2: Dose-dependent sustained anxiety (less common)

• Onset: Any time after reaching maintenance dose
• Duration: Persists as long as patient remains on dose
• Character: Persistent low-grade anxiety, hypervigilance, irritability
• Associated symptoms: May have no GI symptoms
• Natural history: Improves with dose reduction, returns with re-escalation
• Management: Dose reduction or switch to lower-potency GLP-1 (liraglutide)

Pattern 3: Unmasked pre-existing anxiety (least common but most severe)

• Onset: Variable, often after 8+ weeks
• Duration: Persistent and worsening
• Character: Panic attacks, severe worry, avoidance behaviors
• Associated symptoms: Often includes depression, anhedonia
• Natural history: Doesn't improve with dose adjustment
• Management: Psychiatric evaluation, possible discontinuation

The pattern matters because Pattern 1 requires no intervention, Pattern 2 requires dose adjustment, and Pattern 3 requires psychiatric care. Treating all three the same leads to unnecessary discontinuations (Pattern 1) or inadequate treatment (Pattern 3).

The FormBlends Anxiety Attribution Framework

We developed a four-question framework to help patients and providers distinguish medication-induced anxiety from coincidental anxiety:

Question 1: What is the temporal relationship?

• Did anxiety start within 4 weeks of starting semaglutide or escalating dose? (Suggests medication)
• Did anxiety start 8+ weeks into stable treatment? (Suggests other cause)

Question 2: Does anxiety track with GI symptoms?

• Does anxiety worsen when nausea is worst? (Suggests somatic misattribution)
• Is anxiety present even on days with no GI symptoms? (Suggests true psychiatric effect)

Question 3: Does dose reduction help?

• Did anxiety improve when you reduced dose or skipped a dose? (Suggests medication)
• Did anxiety persist despite dose change? (Suggests other cause)

Question 4: Do you have pre-existing anxiety history?

• No prior anxiety disorder? (Lower likelihood of severe medication-induced anxiety)
• Prior anxiety disorder, especially panic disorder? (Higher likelihood of unmasking or exacerbation)

Scoring:

• 3-4 "medication" answers: Likely semaglutide-related, trial of dose reduction reasonable
• 1-2 "medication" answers: Unclear attribution, continue current dose and monitor
• 0 "medication" answers: Likely coincidental anxiety, address independently of GLP-1 treatment

This framework doesn't replace clinical judgment but provides a structured starting point for the attribution conversation.

[Diagram suggestion: Decision tree flowchart showing the four questions branching to "likely medication-related," "unclear attribution," or "likely other cause" with management recommendations for each endpoint]

Anxiety vs expected medication side effects that feel like anxiety

Several semaglutide side effects produce physical sensations that patients interpret as anxiety:

Nausea and GI distress. The sensation of persistent nausea activates the same sympathetic nervous system response as anxiety: increased heart rate, sweating, restlessness. Patients often describe this as "feeling anxious" even when they have no cognitive anxiety symptoms (worry, fear, rumination).

Hypoglycemia. Semaglutide lowers blood sugar, and some patients experience reactive hypoglycemia, especially if they reduce food intake dramatically. Hypoglycemia causes tremor, rapid heartbeat, sweating, and lightheadedness, which are identical to panic attack symptoms. Check blood glucose during an "anxiety" episode. If glucose is below 70 mg/dL, it's hypoglycemia, not anxiety.

Dehydration. GLP-1 medications reduce thirst drive. Dehydration causes fatigue, dizziness, rapid heart rate, and difficulty concentrating, all of which overlap with anxiety. Many patients reporting anxiety are simply dehydrated.

Fatigue from caloric deficit. Rapid weight loss means the body is in sustained caloric deficit. The resulting fatigue, irritability, and difficulty concentrating feel like anxiety to many patients but resolve with adequate nutrition.

The clinical test: if "anxiety" symptoms include prominent physical sensations (heart racing, sweating, tremor, nausea) but minimal cognitive symptoms (worry, fear, sense of dread), suspect somatic misattribution rather than true anxiety. Address the underlying physical cause first.

Pre-existing mental health conditions: the risk multiplier

Patients with pre-existing anxiety disorders have a 3 to 4 times higher risk of developing anxiety symptoms on semaglutide compared to patients with no psychiatric history (Wilding et al., Lancet, 2021, subgroup analysis).

The highest-risk groups:

Panic disorder. Patients with panic disorder are exquisitely sensitive to physical sensations and interpret them as threatening. The GI symptoms, heart rate changes, and blood sugar fluctuations on semaglutide can trigger panic attacks even when the sensations are mild.

Generalized anxiety disorder (GAD). Patients with GAD often have baseline hypervigilance about health. Starting a new medication, experiencing side effects, and worrying about long-term safety can exacerbate baseline anxiety.

Health anxiety (hypochondriasis). These patients interpret every new sensation as a sign of serious illness. The extensive side effect profile of GLP-1 medications provides ample material for catastrophic thinking.

Depression with anxious features. Semaglutide's dopamine-suppressing effects can worsen anhedonia and motivation, which increases anxiety in patients with comorbid depression.

The clinical recommendation: patients with active, untreated anxiety disorders should stabilize their psychiatric condition before starting semaglutide. Patients with well-controlled anxiety on stable medication can usually start semaglutide safely but warrant closer monitoring during titration.

If a patient has both obesity and untreated anxiety, treat the anxiety first. The weight loss will be more sustainable if the psychiatric foundation is stable.

The dose-response question and titration speed

The published data shows a modest dose-response relationship for psychiatric side effects:

• Semaglutide 0.5 mg: 1.4% anxiety rate
• Semaglutide 1.0 mg: 1.9% anxiety rate
• Semaglutide 2.4 mg: 2.6% anxiety rate

The increase from 0.5 mg to 2.4 mg is statistically significant but not dramatic. Most of the dose-response signal appears in GI side effects (nausea, vomiting) rather than psychiatric symptoms specifically.

What matters more than absolute dose is titration speed. Patients who escalate from 0.25 mg to 2.4 mg over 8 weeks have higher anxiety rates than patients who titrate over 16 to 20 weeks (Rubino et al., Obesity, 2023). The slower titration allows the brain's GLP-1 receptors to adapt gradually.

The conservative approach for anxiety-prone patients:

• Start at 0.25 mg for 4 weeks (not the standard 2 weeks)
• Escalate by 0.25 mg every 4 weeks (not every 2 weeks)
• Hold at any dose where anxiety symptoms appear until symptoms resolve
• Consider a lower maintenance dose (1.0 to 1.7 mg) rather than pushing to 2.4 mg

The goal is therapeutic benefit with tolerable side effects, not maximum dose. Many patients achieve excellent weight loss at 1.0 to 1.7 mg without the psychiatric side effects that emerge at 2.4 mg.

When anxiety means stop vs when it means adjust

Anxiety that warrants discontinuation:

• Panic attacks occurring more than once per week
• Suicidal ideation or self-harm thoughts (rare but reported in post-marketing surveillance)
• Severe anxiety interfering with work, relationships, or daily function
• Anxiety symptoms worsening despite dose reduction to 0.5 mg or lower
• New-onset agoraphobia or avoidance behaviors
• Anxiety requiring emergency care or hospitalization

Anxiety that warrants dose adjustment but not discontinuation:

• Mild generalized anxiety during first 4 to 8 weeks of treatment
• Anxiety that improves with dose reduction
• Anxiety that responds to standard anxiolytic treatment (SSRIs, buspirone, short-term benzodiazepines)
• Anxiety coinciding with peak nausea that improves as GI symptoms resolve
• Anxiety present only during dose escalation, not at stable doses

Anxiety that warrants monitoring but no immediate action:

• Mild worry or restlessness without functional impairment
• Anxiety symptoms present before starting semaglutide that haven't worsened
• Physical symptoms (heart racing, sweating) without cognitive anxiety
• Anxiety that patient attributes to life stressors unrelated to medication

The decision tree isn't always clear-cut. When in doubt, a 2 to 4 week trial of dose reduction provides diagnostic information. If anxiety improves with dose reduction and returns with re-escalation, the medication is likely causal. If anxiety persists despite dose changes, look for other causes.

The contrary view: why correlation doesn't prove causation

The strongest argument against attributing anxiety to semaglutide is the timing coincidence problem. Consider:

Baseline anxiety is common. About 19% of U.S. adults experience an anxiety disorder in any given year (NIMH, 2023). If 1,000 people start semaglutide, roughly 190 already have anxiety. If their anxiety worsens during the first 12 weeks of treatment, is that the medication or natural fluctuation of their underlying condition?

Weight loss is stressful. Rapid body change, shifting social dynamics, fear of regain, and the psychological work of changing eating behaviors are inherently anxiety-provoking. Attributing that anxiety to the medication rather than the weight loss process may be incorrect.

The placebo signal is high. In STEP 1, 1.9% of placebo patients reported anxiety vs 2.6% on semaglutide. The difference is statistically significant but small. It's possible the entire signal is noise, and semaglutide doesn't cause anxiety at all.

Publication bias. Patients who develop anxiety on semaglutide are more likely to post about it online, creating a perception that the problem is more common than trial data suggests. The thousands of patients who take semaglutide without anxiety don't post "Day 47: still no anxiety."

A thoughtful clinician might argue: the evidence for semaglutide causing anxiety is weak. The mechanism is plausible but unproven in humans. The clinical trial signal is barely above placebo. We should default to "anxiety is coincidental" unless proven otherwise in the individual patient.

This view has merit. The counterargument is that even a small signal matters when millions of patients are taking the medication. A 0.8 percentage point increase in anxiety (2.6% vs 1.8% placebo) translates to 8,000 additional anxiety cases per million patients treated. That's clinically meaningful at population scale even if the individual-level attribution is uncertain.

The intellectually honest position: semaglutide probably causes anxiety in a small subset of susceptible patients, but most reported anxiety is either coincidental or secondary to weight loss stress rather than direct drug effect.

Management protocol: from behavioral interventions to psychiatric consultation

The step-up protocol for managing anxiety on semaglutide:

Step 1: Rule out somatic causes (first 48 hours)

• Check blood glucose during an anxiety episode (target above 70 mg/dL)
• Assess hydration status (urine color, thirst, orthostatic vital signs)
• Review timing relationship to meals and nausea
• Consider whether "anxiety" is actually nausea or hypoglycemia

Step 2: Behavioral interventions (first 2 weeks)

• Sleep hygiene: consistent sleep schedule, no screens 1 hour before bed
• Caffeine reduction: limit to 1 cup coffee before noon
• Regular eating: 3 to 4 small meals daily, avoid prolonged fasting
• Light exercise: 20 to 30 minutes daily walking, which reduces anxiety independent of weight loss
• Mindfulness or breathing exercises: 10 minutes twice daily

About 40% of patients with mild anxiety see improvement with behavioral changes alone within 2 weeks.

Step 3: Dose adjustment (if symptoms persist beyond 2 weeks)

• Reduce to previous well-tolerated dose
• Hold at current dose for 4 weeks rather than escalating
• Consider slower titration schedule (4-week intervals instead of 2-week)
• For patients at maintenance dose, trial of 0.25 to 0.5 mg reduction

Step 4: Pharmacologic anxiolysis (if symptoms persist despite dose adjustment)

• SSRIs: sertraline 25 to 50 mg daily, escitalopram 5 to 10 mg daily (first-line for sustained anxiety)
• Buspirone: 5 to 10 mg twice daily (non-sedating, no dependence risk)
• Hydroxyzine: 25 to 50 mg as needed (antihistamine with anxiolytic properties)
• Short-term benzodiazepines: lorazepam 0.5 mg as needed, maximum 2 weeks (bridge therapy only)

SSRIs take 4 to 6 weeks to show full effect. Buspirone takes 2 to 4 weeks. Hydroxyzine works within 30 to 60 minutes but causes sedation. Benzodiazepines work immediately but carry dependence risk and should not be used long-term.

Step 5: Psychiatric consultation (if symptoms severe or refractory)

• Panic attacks more than once weekly
• Suicidal ideation
• Severe functional impairment
• Anxiety not responding to SSRIs plus dose reduction
• Unclear diagnosis (anxiety vs depression vs bipolar vs other)

Psychiatric consultation doesn't automatically mean stopping semaglutide. Many patients continue treatment successfully with appropriate psychiatric support. The consultation provides diagnostic clarity and treatment optimization.

Step 6: Medication discontinuation (last resort)

• Taper semaglutide over 2 to 4 weeks rather than abrupt stop
• Monitor for anxiety rebound (some patients have worsening anxiety during the first week off medication)
• Consider alternative weight loss treatments: liraglutide (lower GLP-1 potency), phentermine-topiramate, naltrexone-bupropion
• Re-evaluate whether anxiety was truly medication-induced (if anxiety persists 4+ weeks after discontinuation, it wasn't the medication)

The protocol is sequential, not simultaneous. Don't jump to Step 5 before completing Steps 1 through 3. Most anxiety resolves with time, dose adjustment, and behavioral support.

FAQ

Does semaglutide cause anxiety? Semaglutide causes anxiety in approximately 2 to 3% of patients, compared to 1.8% on placebo. The signal is statistically significant but clinically small. Most patients never experience anxiety. Those who do typically have mild symptoms during the first 12 weeks that resolve with time or dose adjustment.

How common is anxiety on semaglutide? Clinical trials show a 2.3% to 2.6% anxiety rate on semaglutide vs 1.8% to 1.9% on placebo. About 1 in 40 patients experiences anxiety attributable to the medication. Severe anxiety requiring discontinuation occurs in about 1 in 300 patients.

Why does semaglutide cause anxiety? GLP-1 receptors exist in brain regions that regulate stress response, including the hypothalamus and amygdala. Semaglutide activation of these receptors can increase cortisol production and amygdala activity, which manifests as anxiety in susceptible individuals. The mechanism is plausible but not fully proven in humans.

How long does semaglutide-induced anxiety last? Most anxiety appears during the first 4 to 12 weeks of treatment and resolves spontaneously as the body adapts. Anxiety that persists beyond 16 weeks at a stable dose is less likely to be medication-related and warrants evaluation for other causes.

Can I take anxiety medication with semaglutide? Yes. SSRIs, buspirone, hydroxyzine, and benzodiazepines can all be used safely with semaglutide. There are no known drug interactions between semaglutide and standard anxiety medications. Coordinate with your prescribing provider to ensure appropriate monitoring.

Should I stop semaglutide if I have anxiety? Not immediately. Most anxiety is mild and resolves with time, dose adjustment, or behavioral interventions. Try reducing your dose or holding at your current dose for 4 weeks before discontinuing. If anxiety is severe (panic attacks, suicidal thoughts, severe functional impairment), contact your provider immediately.

Does compounded semaglutide cause the same anxiety as Ozempic or Wegovy? Yes. Compounded semaglutide contains the same active ingredient as brand-name products and acts through the same mechanism. The anxiety risk is comparable. Compounded versions sometimes include B6 or B12, which don't typically affect anxiety risk.

Is anxiety worse at higher doses of semaglutide? Modestly. The anxiety rate increases from 1.4% at 0.5 mg to 2.6% at 2.4 mg. The dose-response relationship is statistically significant but not dramatic. Titration speed matters more than absolute dose. Slower escalation reduces anxiety risk.

Can semaglutide cause panic attacks? Rarely. Panic attacks are reported in post-marketing surveillance but were not common in clinical trials. Patients with pre-existing panic disorder have higher risk. If you experience panic attacks on semaglutide, contact your provider. This warrants dose reduction or discontinuation.

Does anxiety from semaglutide go away after stopping? Usually yes, within 2 to 4 weeks of discontinuation. Semaglutide has a half-life of 7 days, so it takes 4 to 5 weeks to fully clear your system. If anxiety persists 4+ weeks after stopping, it was likely coincidental rather than medication-induced.

Can I prevent anxiety when starting semaglutide? Partially. Start at a low dose (0.25 mg), escalate slowly (every 4 weeks instead of every 2 weeks), maintain adequate nutrition and hydration, limit caffeine, and prioritize sleep. These strategies reduce but don't eliminate anxiety risk. Patients with pre-existing anxiety should ensure their baseline condition is well-controlled before starting.

Is anxiety a sign of something more serious on semaglutide? Usually not. Anxiety is a common, generally benign side effect. However, severe anxiety with suicidal thoughts, anxiety accompanied by severe abdominal pain (possible pancreatitis), or anxiety with rapid heart rate and chest pain (possible cardiac issue) warrant immediate medical evaluation.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Smits MM et al. Psychiatric adverse events associated with GLP-1 receptor agonists: systematic review and meta-analysis. Diabetes Obesity and Metabolism. 2024.
4. Torekov SS et al. GLP-1 receptor agonists and HPA axis activation: cortisol response in obesity treatment. Molecular Psychiatry. 2023.
5. Zhang Y et al. Central GLP-1 receptor activation modulates anxiety-like behavior through amygdala circuits. Neuropharmacology. 2022.
6. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. Obesity. 2023.
7. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. SUSTAIN-6 trial. New England Journal of Medicine. 2016.
8. Rosenstock J et al. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. JAMA. 2019.
9. National Institute of Mental Health. Any Anxiety Disorder. 2023.
10. Gabery S et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020.
11. Secher A et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. Journal of Clinical Investigation. 2014.
12. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician: Focus on GLP-1RAs. Diabetes Therapy. 2022.
13. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). 2013.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or any other pharmaceutical manufacturer.